Keele et al. (2026)
- Authors: Gregory R. Keele, Mike Enger, Quinn Barnette, Roman Ruiz-Esparza, Manuel Alvarado, Ravi Mathur, Jeran K. Stratford, Stephanie N. Giamberardino, Linda Morris Brown, Bradley T. Webb, Megan Ulmer Carnes
- Institutes: RTI International, Research Triangle Park, NC, USA, Department of Population Health Sciences, Geisinger, Danville, PA, USA, Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, USA
- Publisher: International Journal of Molecular Sciences
- Link: DOI
Summary
This comprehensive re-analysis of multiple ME/CFS datasets confirms that mitochondrial dysregulation is a consistent biological feature of the disease across different tissues and study populations. By identifying specific genes linked to both the disease and existing medications, the study provides a roadmap for drug repurposing, potentially speeding up the discovery of effective treatments. The findings highlight the critical role of energy production failures in the cellular biology of ME/CFS patients.
What was researched?
Researchers performed a systematic re-analysis of gene and protein expression data from multiple ME/CFS studies and the DecodeME GWAS to find consistent molecular signatures. They specifically looked for evidence of shared biological pathways and potential targets for existing medications.
Why was it researched?
ME/CFS lacks established biomarkers and FDA-approved treatments, largely due to the clinical heterogeneity of the patient population. Standardizing the analysis of existing data helps identify robust biological patterns that smaller, individual studies might miss.
How was it researched?
The team applied a unified bioinformatics pipeline to four bulk gene expression datasets, one single-cell dataset, and four proteomic datasets from the mapMECFS repository. They also integrated genetic data from 15,579 cases in the DecodeME study and used the Realomics tool to match associated genes with potential drug candidates.
What has been found?
Two mitochondrial genes, MT-RNR1 and MT-RNR2, showed consistently lower expression across studies, while other mitochondrial genes showed increased expression in platelets. The analysis identified 201 FDA-approved compounds as potential candidates for drug repurposing, including thiamine 💊, dimethyl fumarate 💊, and ruxolitinib 💊. The study also noted increased mitochondrial gene expression in platelets, supporting the theory of platelet hyperactivation in patients.
Discussion
A significant limitation remains the low consistency of specific individual genes across different studies, likely due to small sample sizes and diverse study designs. However, the convergence on mitochondrial pathways suggests these are reliable biological markers despite technical variations between datasets.
Conclusion & Future Work
The study concludes that mitochondrial dysfunction is a core feature of ME/CFS and demonstrates the high value of secondary data analysis for therapeutic discovery. Future research should focus on larger multi-omic studies and clinical trials of the identified drug candidates.